About: Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
Creator	Davidson, Brian Barry, Aisling Bridgewater, John Hawkins, Maria Hawkins, M Lim, Young-Suk Scorsetti, Marta Apisarnthanarax, Smith Dawson, Laura Apisarnthanarax, S Beecroft, Robert Bridgewater, J Cavallucci, David Diehl, Adam Galvin, Zita O'kane, Grainne Salem, Riad Sapisochin, Gonzalo Schuffenegger, Pablo Sham, Jonathan Solbiati, Luigi Yoon, Sang
Source	Elsevier; Medline; PMC
abstract	Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.
has issue date	2020-06-06(xsd:dateTime)
bibo:doi	10.1016/s2468-1253(20)30182-5
bibo:pmid	32511951
has license	no-cc
sha1sum (hex)	f72c6fbc65eed0c149730422378f0e49e84de693
schema:url	https://doi.org/10.1016/s2468-1253%2820%2930182-5
resource representing a document's title	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective
has PubMed Central identifier	PMC7274990
has PubMed identifier	32511951
schema:publication	Lancet Gastroenterol Hepatol
resource representing a document's body	covid:f72c6fbc65eed0c149730422378f0e49e84de693#body_text
is schema:about of	named entity 'decision making' named entity 'multidisciplinary team' named entity 'COVID-19' named entity 'risk' named entity 'pandemic' named entity 'DECISION MAKING' named entity 'RISK' named entity 'BARCELONA' named entity 'PANDEMIC' named entity 'management' named entity 'management' named entity 'multidisciplinary' named entity 'system' named entity 'pandemic' named entity 'multidisciplinary' named entity 'multidisciplinary team' named entity 'decision making' named entity 'carcinoma' named entity 'systemic therapy' named entity 'hepatocellular carcinoma' named entity 'multidisciplinary' named entity 'malignancies' named entity 'COVID-19 pandemic' named entity 'Eisai' named entity 'chemotherapy' named entity 'SARS-CoV-2' named entity 'intensive care units' named entity 'solid organ transplants' named entity 'Italy' named entity 'tyrosine kinase inhibitor' named entity 'SARS-CoV-2' named entity 'hepatology' named entity 'cholangiocarcinoma' named entity 'systemic therapy' named entity 'COVID-19' named entity 'refractory' named entity 'gemcitabine' named entity 'technetium-99' named entity 'tyrosine kinase inhibitor' named entity 'telemedicine' named entity 'adjuvant chemotherapy' named entity 'COVID-19 pandemic' named entity 'surgical resection' named entity 'palliative' named entity 'resectability' named entity 'SARS-CoV-2' named entity 'MRI' named entity 'image registration' named entity 'hepatocellular carcinoma' named entity 'personal protective equipment' named entity 'PubMed' named entity 'SARS-CoV-2' named entity 'lenvatinib' named entity 'neoadjuvant' named entity 'SARS-CoV-2' named entity 'definitive therapy' named entity 'hepatocellular carcinoma' named entity 'surgical oncology' named entity 'potentially infectious' named entity 'tyrosine kinase inhibitors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software